IL107321A - Aztidinones are converted into their preparation and pharmaceutical compositions containing them - Google Patents

Aztidinones are converted into their preparation and pharmaceutical compositions containing them

Info

Publication number
IL107321A
IL107321A IL10732193A IL10732193A IL107321A IL 107321 A IL107321 A IL 107321A IL 10732193 A IL10732193 A IL 10732193A IL 10732193 A IL10732193 A IL 10732193A IL 107321 A IL107321 A IL 107321A
Authority
IL
Israel
Prior art keywords
ch2ch2n
6alkyl
amino
hydrogen
oxo
Prior art date
Application number
IL10732193A
Other languages
English (en)
Hebrew (he)
Other versions
IL107321A0 (en
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL107321A0 publication Critical patent/IL107321A0/xx
Publication of IL107321A publication Critical patent/IL107321A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL10732193A 1992-10-27 1993-10-19 Aztidinones are converted into their preparation and pharmaceutical compositions containing them IL107321A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96680092A 1992-10-27 1992-10-27
US99183892A 1992-12-17 1992-12-17

Publications (2)

Publication Number Publication Date
IL107321A0 IL107321A0 (en) 1994-01-25
IL107321A true IL107321A (en) 1998-08-16

Family

ID=27130493

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10732193A IL107321A (en) 1992-10-27 1993-10-19 Aztidinones are converted into their preparation and pharmaceutical compositions containing them

Country Status (29)

Country Link
EP (1) EP0595557B1 (fr)
JP (1) JPH082868B2 (fr)
KR (1) KR950704250A (fr)
CN (1) CN1043884C (fr)
AT (1) ATE270273T1 (fr)
AU (1) AU663806B2 (fr)
CA (1) CA2108584C (fr)
CY (1) CY2529B1 (fr)
CZ (1) CZ106895A3 (fr)
DE (1) DE69333563T2 (fr)
DK (1) DK0595557T3 (fr)
DZ (1) DZ1724A1 (fr)
ES (1) ES2224095T3 (fr)
FI (1) FI951992A (fr)
HR (1) HRP931309A2 (fr)
HU (2) HUT72084A (fr)
IL (1) IL107321A (fr)
LV (1) LV13338B (fr)
MX (1) MX9306666A (fr)
MY (1) MY128261A (fr)
NO (1) NO305697B1 (fr)
NZ (1) NZ257755A (fr)
PL (1) PL308545A1 (fr)
PT (1) PT595557E (fr)
RU (1) RU2148056C1 (fr)
SI (1) SI9300566A (fr)
SK (1) SK53795A3 (fr)
TW (1) TW275621B (fr)
WO (1) WO1994010142A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420010A (en) * 1993-07-30 1995-05-30 Merck & Co., Inc. Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
US5523233A (en) * 1995-05-03 1996-06-04 Merck & Co., Inc. Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters
US5808056A (en) * 1995-10-31 1998-09-15 Merck & Co., Inc. Process for preparing substituted azetidinones
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
EP0869943A1 (fr) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose
JP2000509049A (ja) * 1996-04-26 2000-07-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療用アゼチジノン誘導体
WO2000005204A1 (fr) * 1998-07-23 2000-02-03 Shionogi & Co., Ltd. COMPOSES DE β-LACTAME MONOCYCLIQUES ET INHIBITEURS DE LA CHYMASE LES RENFERMANT
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
FR2937972B1 (fr) * 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
WO2010104024A1 (fr) * 2009-03-09 2010-09-16 大鵬薬品工業株式会社 Composé de pipérazine capable d'inhiber la prostaglandine d synthase
FR2981933B1 (fr) * 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (fr) * 1991-06-25 1993-01-07 Merck & Co., Inc. Azetidinones substituees utilisees comme agents antiinflammatoires et antidegeneratifs

Also Published As

Publication number Publication date
CN1090272A (zh) 1994-08-03
DE69333563D1 (de) 2004-08-05
WO1994010142A1 (fr) 1994-05-11
CA2108584A1 (fr) 1994-04-28
ATE270273T1 (de) 2004-07-15
EP0595557A1 (fr) 1994-05-04
AU663806B2 (en) 1995-10-19
DZ1724A1 (fr) 2002-02-17
RU95109936A (ru) 1997-01-10
MY128261A (en) 2007-01-31
RU2148056C1 (ru) 2000-04-27
DK0595557T3 (da) 2004-10-25
NO951593L (no) 1995-06-23
CY2529B1 (en) 2006-04-12
LV13338B (en) 2006-01-20
HRP931309A2 (en) 1997-02-28
HU211619A9 (en) 1995-12-28
HU9501184D0 (en) 1995-06-28
JPH06263723A (ja) 1994-09-20
CN1043884C (zh) 1999-06-30
TW275621B (fr) 1996-05-11
HUT72084A (en) 1996-03-28
PT595557E (pt) 2004-10-29
CA2108584C (fr) 1998-11-24
NO305697B1 (no) 1999-07-12
NO951593D0 (no) 1995-04-26
AU5028393A (en) 1994-05-12
NZ257755A (en) 1998-03-25
KR950704250A (ko) 1995-11-17
FI951992A0 (fi) 1995-04-26
DE69333563T2 (de) 2005-08-18
CZ106895A3 (en) 1996-03-13
IL107321A0 (en) 1994-01-25
JPH082868B2 (ja) 1996-01-17
SK53795A3 (en) 1995-09-13
EP0595557B1 (fr) 2004-06-30
FI951992A (fi) 1995-04-26
SI9300566A (en) 1994-09-30
PL308545A1 (en) 1995-08-21
ES2224095T3 (es) 2005-03-01
MX9306666A (es) 1994-04-29

Similar Documents

Publication Publication Date Title
LV13338B (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
ES2219894T3 (es) Derivados heterociclicos que inhiben el factor xa.
CZ292942B6 (cs) Derivát (N-hydroxykarbamoyl)-1-(4-fenoxy)benzensulfonylu
WO1995021832A1 (fr) Composes pharmaceutiques a base de piperazine
JP2007238458A (ja) 新規なイソキノリン誘導体及びこれを含有する医薬
CA2301742A1 (fr) Pyridines 2,3,5-trisubstituees utilisees comme inhibiteurs de la cyclo-oxygenase 2
MX9704856A (es) Derivados de indazol sustituidos.
US6071903A (en) 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
US5747485A (en) Substituted azetidiones as anti-inflammatory and antidegenerative agents
US5348953A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5591737A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5952321A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
MXPA01012505A (es) Inhibidores de trombina tipo pirazinona.
AU686780B2 (en) Composition for the treatment of lung disease
US6462050B1 (en) Thrombin inhibitors
US6521625B2 (en) Pyrazinone thrombin inhibitors
ZA200109228B (en) $G(A)-amino-$G(B)-sulfonyl hydroxamic acid compounds.
US7026324B2 (en) Thrombin inhibitors
JP2001192398A (ja) セリンプロテアーゼ阻害剤
KR100426545B1 (ko) 세린 프로테아제 억제제
JP2001019678A (ja) 新規な芳香族アミジン誘導体及びその塩

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force